CytRx set to begin phase 3 clinical trial for aldoxorubicin

CytRx (CYTR) set to begin global phase 3 trial for aldoxorubicin as a second-line treatment for soft tissue sarcoma (STS) after the phase 2 trial demonstrated 80 - 100% superiority of doxorubicin in median progression-free survival (PFS), 6-month PFS and overall response rate.

Under a Special Protocol Assessment from the FDA, the phase 3 trial will target STS patients who have relapsed or are refractory following prior chemotherapy treatment. In January, the FDA approved continued dosing until disease progression.

Two phase trials are underway for assess the safety and efficacy of aldoxorubicin in patients with unresectable glioblastoma multiforme and Kaposi's sarcoma.

Quick assets totaled $38.5M at years end.

The company raised $86M in a secondary offering last month.

Mutual fund ownership has increased from 21 to 25 over the past 4 quarters.

From other sites
Comments (2)
  • DrBarriga_
    , contributor
    Comment (1) | Send Message
    this will be a good bargain for the long run, definetely
    5 Mar 2014, 12:27 PM Reply Like
  • corbitt
    , contributor
    Comments (22) | Send Message
    Does anyone know why the phase 3 for STS is treating 2nd line patients, but the 2b was first line? I know the 1/2a was also 2nd line but that was only 13 patients. I'm just surprised that they would switch it up like this. Thanks.
    14 Mar, 10:21 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs